Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 6, 2014, Pages 885-890

  Mariotti, Jacopo ^a   Maura, Francesco ^a   Spina, Francesco ^a   Roncari, Luisa ^a   Dodero, Anna ^a   Farina, Lucia ^a   Montefusco, Vittorio ^a   Carniti, Cristiana ^a   Sarina, Barbara ^b   Patriarca, Francesca ^c   Rambaldi, Alessandro ^d   Onida, Francesco ^e   Olivieri, Attilio ^f   Zallio, Francesco ^g   Corradini, Paolo ^a,h  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g C Arrigo Children's Hospital   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cytomegalovirus (CMV); Lymphoma

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; CANCER MORTALITY; CANCER REGRESSION; CYTOMEGALOVIRUS; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; VIRUS REPLICATION; YOUNG ADULT; ADOLESCENT; ALLOTRANSPLANTATION; BLOOD; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA, B-CELL; MALE; PHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRUS REPLICATION; YOUNG ADULT;

EID: 84899991642     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.02.015     Document Type: Article

References (31)

1. Vose J.M., Bierman P.J., Anderson J.R., et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992, 80:2142-2148.
2. Paltiel O., Rubinstein C., Or R., et al. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant 2003, 31:565-569.
3. Corradini P., Dodero A., Farina L., et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007, 21:2316-2323.
4. Boeckh M., Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103:2003-2008.
5. Elmaagacli A.H., Steckel N.K., Koldehoff M., et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011, 118:1402-1412.
6. Lönnqvist B., Ringdèn O., Ljungman P., et al. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol 1986, 63:671-679.
7. Jacobsen N., Lönnqvist B., Ringdén O., et al. Graft-versus-leukaemia activity associated with cytomegalovirus seropositive bone marrow donors but separated from graft-versus-host disease in allograft recipients with AML. Eur J Haematol 1987, 38:350-355.
8. Boström L., Ringdén O., Nilsson B., et al. Early leukaemia, seropositivity for several herpes viruses and chronic graft-versus-host disease are associated with decreased incidence of relapse after allogeneic bone marrow transplantation. Clin Transplant 1991, 5:351-358.
9. Green M.L., Leisenring W.M., Xie H., et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 2013, 122:1316-1324.
10. Gratwohl A. Principles of conditioning. In: Apperley J, Carreras E, Gluckman E, et al. The ESH-EBMT handbook on hematopoietic stem cell transplantation 2008:129-144.
11. Corradini P., Tarella C., Olivieri A., et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002, 99:75-82.
12. Sarina B., Castagna L., Farina L., et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010, 115:3671-3677.
13. Rambaldi A., Bacigalupo A., Fanin R., et al. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. Leukemia 2012, 26:1779-1785.
14. Kumar A., Mhaskar A.R., Reljic T., et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia 2012, 26:582-588.
15. Chakraverty R., Orti G., Roughton, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 2010, 116:3080-3088.
16. Cheson B.D., Pfistner B., Juweid M.E., et al. International Harmonization Project on Lymphoma Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
17. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974, 18:295-304.
18. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
19. Trenschel R., Ross S., Hüsing J., et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant 2000, 25:665-672.
20. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
21. Scheper W., van Dorp S., Kersting S., et al. γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 2013, 27:1328-1338.
22. Nachbaur D., Bonatti H., Oberaigner W., et al. Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet 2001, 358:1157-1159.
23. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007, 110:2744-2748.
24. Tomblyn M., Brunstein C., Burns L.J., et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:538-545.
25. Baron F., Storb R., Storer B.E., et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006, 24:4150-4157.
26. Schmidt-Hieber M., Labopin M., Beelen D., et al. CMV serostatus has still an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 2013, 122:3359-3364.
27. Foley B., Cooley S., Verneris M.R., et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012, 119:2665-2674.
28. Della Chiesa M., Falco M., Podestà M., et al. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. Blood 2012, 119:399-410.
29. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
30. Prinz I., Thamm K., Port M., et al. Donor Vδ1+ γδ T cells expand after allogeneic hematopoietic stem cell transplantation and show reactivity against CMV-infected cells but not against progressing B-CLL. Exp Hematol Oncol 2013, 2:14.
31. Boeckh M., Nichols W.G., Papanicolaou G., et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003, 9:543-558.